Board Meeting8 Aug 2026, 04:10 pm
Akums Drugs Declares Un-audited Standalone & Consolidated Results
AI Summary
Akums Drugs and Pharmaceuticals Limited announced its Un-audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors approved these results during a meeting held on August 08, 2026. The company also submitted a Statement of Deviation pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The independent auditor's review report was also provided. A tax demand of ₹600.92 million for a prior period block has been noted, with the company filing an appeal.
Key Highlights
- Un-audited financial results for Q1 FY27 declared.
- Results are both standalone and consolidated.
- Board meeting held on August 08, 2026, approved results.
- Limited Review Reports from auditors are enclosed.
- Tax demand of ₹600.92 million noted; appeal filed.
Price Impact
More from AKUMS